Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1972 1
1973 4
1974 2
1975 1
1976 3
1977 2
1978 6
1979 13
1980 6
1981 1
1982 3
1983 13
1984 4
1985 12
1986 39
1987 9
1988 14
1989 16
1990 14
1991 26
1992 14
1993 29
1994 17
1995 14
1996 41
1997 15
1998 29
1999 28
2000 27
2001 10
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

413 results
Results by year
Filters applied: . Clear all
Page 1
Antiphospholipid-thrombosis syndromes.
Bick RL, Arun B, Frenkel EP. Bick RL, et al. Haemostasis. 1999;29(2-3):100-10. doi: 10.1159/000022492. Haemostasis. 1999. PMID: 10629391 Review.
Antiphospholipid antibodies are strongly associated with thrombosis and appear to be the most common of the acquired blood protein defects causing thrombosis. Based upon our experience, approximately 25% of patients with unexplained venous thrombosis, approxi …
Antiphospholipid antibodies are strongly associated with thrombosis and appear to be the most common of the acquired blood protein de …
Pathogenesis of thrombosis.
Prentice CR. Prentice CR. Haemostasis. 1990;20 Suppl 1:50-9. doi: 10.1159/000216161. Haemostasis. 1990. PMID: 2083873 Review.
The pathogenesis of thrombosis involves consideration of two processes: atherosclerosis and thrombosis. ...In veins the atherosclerotic process does not occur, and thrombosis is precipitated by immobility often associated with accidental or surgical trauma. . …
The pathogenesis of thrombosis involves consideration of two processes: atherosclerosis and thrombosis. ...In veins the athero …
Heparin-induced thrombocytopenia.
Kelton JG. Kelton JG. Haemostasis. 1986;16(2):173-86. doi: 10.1159/000215288. Haemostasis. 1986. PMID: 3519379 Review.
Finally, a small subset of patients with heparin-induced thrombocytopenia develop the disastrous complication of heparin-induced thrombocytopenia plus arterial thrombosis. Some of these patients die. In this review, we will summarize some of the issues concerning heparin-i …
Finally, a small subset of patients with heparin-induced thrombocytopenia develop the disastrous complication of heparin-induced thrombocyto …
Cancer and thrombosis.
Donati MB. Donati MB. Haemostasis. 1994 Mar-Apr;24(2):128-31. doi: 10.1159/000217092. Haemostasis. 1994. PMID: 7959360 Review.
Thrombosis is the most frequent complication and the second cause of death in patients with overt malignant disease. ...Recently, emphasis has been given to the potential risk of cancer therapy (both surgery and chemotherapy) in enhancing the risk for thromboembolic diseas …
Thrombosis is the most frequent complication and the second cause of death in patients with overt malignant disease. ...Recently, emp …
Venous thrombosis: prevalence and interaction of risk factors.
Rosendaal FR. Rosendaal FR. Haemostasis. 1999 Dec;29 Suppl S1:1-9. doi: 10.1159/000054106. Haemostasis. 1999. PMID: 10629398 Review.
The key to understanding why certain individuals develop deep vein thrombosis at varying times, despite similar risk factors being present, is the realization of the importance of gene-gene and gene-environment interactions between risk factors. The discovery of factor V L …
The key to understanding why certain individuals develop deep vein thrombosis at varying times, despite similar risk factors being pr …
Paroxysmal nocturnal hemoglobinuria and the risk of venous thrombosis: review and recommendations for management of the pregnant and nonpregnant patient.
Ray JG, Burows RF, Ginsberg JS, Burrows EA. Ray JG, et al. Haemostasis. 2000 May-Jun;30(3):103-17. doi: 10.1159/000022532. Haemostasis. 2000. PMID: 11014960 Review.
The likely cause of death among patients with paroxysmal nocturnal hemoglobinuria was described in nine studies: 22.2% of fatalities were due to venous thrombosis (95% CI 11.8-38.0), more commonly in western countries (event rate 37.2%, 95% CI 21.6-56.0). ...CONCLUSION: In …
The likely cause of death among patients with paroxysmal nocturnal hemoglobinuria was described in nine studies: 22.2% of fatalities were du …
Venous thrombosis today.
Kakkar VV. Kakkar VV. Haemostasis. 1994 Mar-Apr;24(2):86-104. doi: 10.1159/000217089. Haemostasis. 1994. PMID: 7959367 Review.
The epidemiology of the disease has been investigated, defining patient groups at risk. Safe and effective methods of venous thrombosis prophylaxis have been evaluated in a wide range of patient populations, and recommendations for their application have been widely dissem …
The epidemiology of the disease has been investigated, defining patient groups at risk. Safe and effective methods of venous thrombosis …
Standardization of plasminogen assays.
Gaffney PJ. Gaffney PJ. Haemostasis. 1988;18 Suppl 1:47-60. doi: 10.1159/000215837. Haemostasis. 1988. PMID: 3280425 Review.
Plasmin potency estimates. Influence of substrate used in assay. Thrombosis and Haemostasis 1981, 45, 107-109). Activation procedures of plasminogen and subsequent assays of plasmin using a variety of substrates have been recently superseded by an assay which involves the …
Plasmin potency estimates. Influence of substrate used in assay. Thrombosis and Haemostasis 1981, 45, 107-109). Activation procedures …
New antithrombotic agents for the prevention and treatment of deep vein thrombosis.
Boneu B. Boneu B. Haemostasis. 1996 Oct;26 Suppl 4:368-78. doi: 10.1159/000217318. Haemostasis. 1996. PMID: 8979141 Review.
Besides low molecular weight heparins (LMWHs) a number of new antithrombotic agents have been evaluated mainly in the prevention of deep vein thrombosis (DVT) and, to a lesser extent, in the treatment of established DVT. ...
Besides low molecular weight heparins (LMWHs) a number of new antithrombotic agents have been evaluated mainly in the prevention of deep vei …
Past, present and future of hirudin.
Markwardt F. Markwardt F. Haemostasis. 1991;21 Suppl 1:11-26. doi: 10.1159/000216258. Haemostasis. 1991. PMID: 1894186 Review.
The efficacy of hirudin in preventing venous and arterial thrombosis and disseminated intravascular coagulation was demonstrated in various animal models. ...
The efficacy of hirudin in preventing venous and arterial thrombosis and disseminated intravascular coagulation was demonstrated in v …
413 results